Since CCL3 can enhance the therapeutic effect of immune checkpoint inhibitors (like PD-1 inhibitors) [34], a reduction in CCL3 expression in PBMCs of CRC patients implies that patients could respond less effectively to immunotherapies that depend on strong immune cell infiltration. Here, CCL3 is linked to colorectal carcinoma.